Key Takeaways XRAY's Imaging segment gains from Orthophos SL and Primescan 2 relaunches might have support Q2 growth.Byte suspension likely continued to be a 200bps headwind on XRAY's organic sales, limiting overall progress.XRAY's cost initiatives and SKU rationalization may have stabilized gross margins, aiding Q/Q Q2 growth.DENTSPLY SIRONA Inc. (XRAY) is scheduled to release second-quarter 2025 results on Aug. 7, before the opening bell.In the last reported quarter, the company’s earnings beat the Zacks ...